Growing community of inventors

Newton, MA, United States of America

Maria Vilenchik

Average Co-Inventor Count = 5.91

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 3

Maria VilenchikMichael Frid (4 patents)Maria VilenchikAlexandra Kuznetsova (4 patents)Maria VilenchikYuriy Gankin (3 patents)Maria VilenchikMarc Duey (3 patents)Maria VilenchikMichal Galezowski (1 patent)Maria VilenchikWojciech Czardybon (1 patent)Maria VilenchikCharles-Henry Fabritius (1 patent)Maria VilenchikAgnieszka Dreas (1 patent)Maria VilenchikAnna Buda (1 patent)Maria VilenchikGeorgiy Kachkovskyi (1 patent)Maria VilenchikUrszula Kulesza (1 patent)Maria VilenchikKatarzyna Kucwaj-Brysz (1 patent)Maria VilenchikAgnieszka Szamborska-Gbur (1 patent)Maria VilenchikAndrzej Dzienia (1 patent)Maria VilenchikMicheal Frid (0 patent)Maria VilenchikMaria Vilenchik (4 patents)Michael FridMichael Frid (5 patents)Alexandra KuznetsovaAlexandra Kuznetsova (4 patents)Yuriy GankinYuriy Gankin (3 patents)Marc DueyMarc Duey (3 patents)Michal GalezowskiMichal Galezowski (6 patents)Wojciech CzardybonWojciech Czardybon (5 patents)Charles-Henry FabritiusCharles-Henry Fabritius (4 patents)Agnieszka DreasAgnieszka Dreas (2 patents)Anna BudaAnna Buda (1 patent)Georgiy KachkovskyiGeorgiy Kachkovskyi (1 patent)Urszula KuleszaUrszula Kulesza (1 patent)Katarzyna Kucwaj-BryszKatarzyna Kucwaj-Brysz (1 patent)Agnieszka Szamborska-GburAgnieszka Szamborska-Gbur (1 patent)Andrzej DzieniaAndrzej Dzienia (1 patent)Micheal FridMicheal Frid (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Felicitex Therapeutics, Inc. (4 from 4 patents)

2. Selvita S.a. (1 from 5 patents)

3. Ryvu Therapeutics S.a. (3 patents)


4 patents:

1. 11202779 - Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors

2. 10577365 - Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases

3. 10322128 - Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors

4. 10314843 - Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/27/2025
Loading…